Accueil   Diary - News   All news PDC*line Pharma raises €17.5 million in Series B2 financing round

PDC*line Pharma raises €17.5 million in Series B2 financing round

 

New funding includes €11.8M in equity and €5.7M in grants. It completes the €20M B1 round of financing announced in January 2020

 

Proceeds will primarily be used to fund company’s phase I/II trial with PDC*lung01, a vaccine candidate for lung cancer

 

 

 

Liège, Belgium and Grenoble, France, December 6, 2021 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active off-the-shelf cancer vaccine, announces today the completion of its Series B2 round of financing. The company has raised a total of €17.5 million ($20.3M) with Belgian and South-Korean investors.

 

Less than two years after its €20M B1 round of fundraising, announced in January 2020, PDC*line Pharma has attracted new investors and secured a further capital increase of €11.8M. In addition, the company has received a €5.7M grant in repayable aid from the Walloon Region of Belgium, which has backed the company since its arrival in 2016. The company will therefore have raised a total of €37.5M euros in this series B round.

 

 

Read the press release